SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-216147
Filing Date
2022-08-09
Accepted
2022-08-09 16:08:53
Documents
14
Period of Report
2022-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d348230d8k.htm   iXBRL 8-K 23194
2 EX-99.1 d348230dex991.htm EX-99.1 80277
6 GRAPHIC g348230g0809140042403.jpg GRAPHIC 4581
  Complete submission text file 0001193125-22-216147.txt   241477

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvmd-20220809.xsd EX-101.SCH 2893
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvmd-20220809_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvmd-20220809_pre.xml EX-101.PRE 10837
8 EXTRACTED XBRL INSTANCE DOCUMENT d348230d8k_htm.xml XML 3234
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

IRS No.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39219 | Film No.: 221148332
SIC: 2836 Biological Products, (No Diagnostic Substances)